Pulmonx(LUNG) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total worldwide revenue in Q4 2025 was $22.6 million, a 5% decrease from $23.8 million in Q4 2024, and a 7% decrease on a constant currency basis [19] - Full year 2025 revenue was $90.5 million, an 8% increase over the prior year, and a 7% increase on a constant currency basis [19] - U.S. revenue in Q4 2025 was $14.1 million, an 11% decrease from $15.9 million in Q4 2024, while full year U.S. revenue was $57 million, a 1% increase over the prior year [19] - International revenue in Q4 2025 was $8.5 million, an 8% increase from $7.9 million in Q4 2024, and a 2% increase on a constant currency basis [20] - Gross margin for Q4 2025 was 77.6%, up from 74% in the prior year, driven by a lower mix of distributor sales [21] - Net loss for Q4 2025 was $10.4 million, or a loss of $0.25 per share, compared to a net loss of $13.2 million, or a loss of $0.33 per share in Q4 2024 [24] Business Line Data and Key Metrics Changes - The company added 10 new U.S. treating centers during Q4 2025 [19] - R&D expenses for Q4 2025 were $4.6 million, compared to $4 million in Q4 2024, reflecting increased clinical trial activity [23] - Sales, general, and administrative expenses for Q4 2025 were $22.9 million, down from $27 million in Q4 2024 due to cost controls [23] Market Data and Key Metrics Changes - International revenue for the full year 2025 was $33.5 million, a 23% increase over the prior year, and a 19% increase on a constant currency basis [20] - The company expects revenue growth in the first half of 2026 to be negatively impacted by minimal sales to its distributor in China, with a return to growth expected in the second half [25][26] Company Strategy and Development Direction - The company’s top three priorities are re-accelerating U.S. sales growth, advancing clinical initiatives, and aligning spending to achieve profitability [6] - AeriSeal program is a key focus, with expectations to expand the total addressable market by an estimated 20% globally upon completion of the CONVERT II trial in 2027 [14][15] - The company aims to demonstrate meaningful operating leverage and reduce cash burn from $32 million in 2025 to $23 million in 2026, representing a reduction of nearly 30% [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the underperformance in U.S. revenue was largely due to internal operational challenges and has taken steps to realign the sales organization [6][8] - The company expects U.S. sales growth to resume in the back half of 2026, driven by a refocused commercial strategy and newly filled sales positions [25] - Management remains confident in the business fundamentals and is focused on executing a clear operating plan targeting high-impact initiatives [27] Other Important Information - The company executed a cost restructuring initiative that reduced ongoing operating expenses by over 10% [17] - A $60 million credit facility was closed, extending the maturity of existing debt to 2031 and providing access to additional capital [17] Q&A Session Summary Question: What percentage of the sales force turned over in Q4? - The turnover was across the entire year, with approximately half of the sales organization experiencing turnover [29] Question: How are sales incentives structured now? - The company has embraced a new approach to quota allocation and compensation design, ensuring it is reasonable and well-understood by the sales team [34] Question: Why wouldn't growth return sooner with the new sales force in place? - The company is starting from a position of decline and needs time for the new sales team to ramp up productivity [40] Question: What changes contributed to the 10% cost reduction? - The majority of the savings came from G&A and marketing, while maintaining investments in key growth areas like sales and R&D [45] Question: How is the AeriSeal trial progressing? - Enrollment in the CONVERT II trial is accelerating, and it is not expected to significantly impact overall company spending [52] Question: What is the outlook for China sales? - Minimal sales are expected in the first half of 2026, with a return to shipments anticipated in the back half of the year [78]